Using Stem Cells to Cure Autism, Epilepsy & Schizophrenia | Dr. Sergiu Pașca

What It Covers

Dr. Sergiu Pașca explains how induced pluripotent stem cells enable creation of brain organoids and assembloids to study autism, schizophrenia, and Timothy syndrome, revealing developmental mechanisms and potential gene therapies for profound neurological conditions without using embryonic tissue.

Key Questions Answered

• •Autism prevalence and genetics: Autism now affects nearly 3% of the population, up from rare disease status decades ago. Twenty percent of patients receive genetic diagnosis identifying specific mutations. Males affected at 1:4 ratio compared to females, with strong heritability making it one of most genetic psychiatric disorders known.
• •Yamanaka factors breakthrough: Four genetic factors can reprogram adult skin cells into pluripotent stem cells without using embryonic tissue, eliminating ethical concerns. This 2006 discovery enables unlimited patient-specific neurons for disease modeling, taking months to generate but providing personalized cells for studying any neurological condition in laboratory settings.
• •Organoid developmental timing: Brain organoids grown in dishes follow intrinsic developmental timelines matching human gestation, switching from prenatal to postnatal molecular signatures at nine months without external cues. Cultures maintained for 600-800 days continue maturing, with myelination progressing into third decade, revealing cells possess internal developmental clocks independent of environmental factors.
• •Assembloid circuit formation: Four-part assembloids recreate sensory pathways by combining skin sensory neurons, spinal cord, thalamus, and cortex organoids in correct spatial order. Parts must be positioned properly or cells fail to connect. Within weeks, spontaneous synchronized activity emerges across entire pathway, enabling testing of pain medications and genetic pain disorders.
• •Timothy syndrome modeling: Single calcium channel mutation causing profound autism, epilepsy, and cardiac issues shows measurably prolonged calcium signaling in patient-derived neurons. This represents first genetic form of autism with clear biological mechanism, enabling development of targeted therapies through assembloid testing without animal models, with clinical trials now in preparation.